0000000001135228

AUTHOR

Christiane Dinsart

showing 2 related works from this author

Activation of the human immune system via toll-like receptors by the oncolytic parvovirus H-1.

2012

This study aimed to investigate the function of toll-like receptors (TLRs) during oncolytic parvovirus H-1 (H-1PV)-induced human immune responses. First, the role of TLRs in the activation of the NFκB transcription factor was characterized; second, the immunologic effects of H-1PV-induced tumor cell lysates (TCL) on human antitumor immune responses were evaluated. A human ex vivo model was used to study immune responses with dendritic cells (DCs). Human embryonic kidney cells (HEK293) transfected to stably express TLRs were used as potential human DC equivalents to further investigate the role of specific TLRs during immune activation. TLR3 and TLR9 were activated by H-1PV infection, which …

Cytotoxicity ImmunologicH-1 parvovirusCancer ResearchCytoplasmParvovirus H-1chemical and pharmacologic phenomenaEnzyme-Linked Immunosorbent AssayBiologyKidneyProinflammatory cytokineParvoviridae InfectionsImmune systemTumor Cells CulturedHumansMelanomaCells CulturedCell NucleusOncolytic VirotherapyTumor Necrosis Factor-alphaToll-Like ReceptorsNF-kappa BDendritic CellsAcquired immune systemFlow CytometryCell biologyOncolytic virusOncolytic VirusesOncologyImmune SystemImmunologyTLR3CytokinesTumor necrosis factor alphaSignal transductionSignal TransductionInternational journal of cancer
researchProduct

Rational Combination of Parvovirus H1 With CTLA-4 and PD-1 Checkpoint Inhibitors Dampens the Tumor Induced Immune Silencing

2019

The recent therapeutic success of immune checkpoint inhibitors in the treatment of advanced melanoma highlights the potential of cancer immunotherapy. Oncolytic virus-based therapies may further improve the outcome of these cancer patients. A human ex vivo melanoma model was used to investigate the oncolytic parvovirus H-1 (H-1PV) in combination with ipilimumab and/or nivolumab. The effect of this combination on activation of human T lymphocytes was demonstrated. Expression of CTLA-4, PD-1, and PD-L1 immune checkpoint proteins was upregulated in H-1PV-infected melanoma cells. Nevertheless, maturation of antigen presenting cells such as dendritic cells was triggered by H-1PV infected melanom…

0301 basic medicineCancer ResearchRegulatory T cellmedicine.medical_treatmentIpilimumablcsh:RC254-28203 medical and health sciences0302 clinical medicineimmune cellsCancer immunotherapymedicinemelanomaCytotoxic T cellipilimumabAntigen-presenting cellOriginal Researchnivolumabbusiness.industrylcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensImmune checkpointH-1PV030104 developmental biologymedicine.anatomical_structureOncologyCTLA-4030220 oncology & carcinogenesisCancer researchimmunotherapyNivolumabbusinessmedicine.drugFrontiers in Oncology
researchProduct